- recruitingPHASE2
Study of Dato-DXd as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Tumours (TROPION-PanTumor03)
This study looks at a new drug, Dato-DXd, by itself and with other treatments for different advanced cancers like those affecting the stomach, ovaries, and prostate. It checks if the treatment is safe and effective.
United States · Canada · China - recruitingPHASE2
APL-101 Study of Subjects With NSCLC With c-Met EXON 14 Skip Mutations and c-Met Dysregulation Advanced Solid Tumors
This study is testing a new oral medicine, APL-101, for people with advanced cancers. It focuses on lung cancer and other solid tumours where specific genetic changes linked to a protein called MET are found. Researchers want to see how well it works and if it's safe.
United States · Australia · Canada - active not recruitingPHASE3
AZD0901 Compared With Investigator's Choice of Therapy in Participants With Second- or Later-line Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma Expressing Claudin18.2
This study is testing a new drug, AZD0901, for advanced stomach cancer or where the food pipe meets the stomach. It's for people whose cancer has Claudin18.2 protein and has already been treated before. Researchers want to see if AZD0901 works better and is safer than other treatments.
United States · Brazil · Canada - recruitingPHASE1, PHASE2
Phase 1/2 Study to Evaluate TH9619 in the Treatment of Advanced Solid Tumors
This study is testing a new medicine, TH9619, for people with advanced cancers like bowel, head and neck, lung, and stomach cancer. It's the first time TH9619 is being given to people, and doctors want to find the safest and most effective dose.
France · Spain · United Kingdom - recruitingNA
Augmented Response of Volatile Biomarkers in Assessment of Oesophagogastric Cancer (AROMA 1 / BIORESOURCE)
This study looks for early signs of stomach and gullet cancer using a simple breath test. Researchers hope to make this test more accurate by giving people a special drink to help show up certain chemicals in their breath that are linked to cancer.
United Kingdom - recruitingPHASE2
Ph1b/2 Study of the Safety and Efficacy of T-DXd Combinations in Advanced HER2-expressing Gastric Cancer (DESTINY-Gastric03)
This study looks at new treatments for advanced stomach or oesophageal cancer with a specific protein called HER2. We're testing a new drug, trastuzumab deruxtecan, by itself or with other common cancer medicines to see if it's safe and effective.
United States · Brazil · Canada - recruitingPHASE2
Novel Combinations in Participants With Locally Advanced Unresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
This study is testing new combinations of medicines for advanced stomach or food pipe cancer that has spread or can't be removed by surgery. It aims to see how well they work and if they are safe. Researchers want to find better ways to treat this type of cancer.
United States · China · Japan - recruitingPHASE1, PHASE2
Study of AZD5863 in Adult Participants With Advanced or Metastatic Solid Tumors
This study is testing a new experimental medicine, AZD5863, for people with advanced stomach, oesophageal, or pancreatic cancer. It aims to see if the medicine is safe, what dose works best, and if it can help fight the cancer.
United States · China · France - recruitingPHASE2, PHASE3
DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations
This study is testing a cancer drug called capmatinib to see if it can help adults with different types of cancer that share a specific genetic change (MET mutation). It's already approved for some lung cancers, and now researchers want to know if it works for other cancers too.
United Kingdom - recruitingPHASE1
A Study of PF-08046054/SGN-PDL1V in Advanced Solid Tumors
This study is testing a new drug, PF-08046054/SGN-PDL1V, alone and with an existing medicine called pembrolizumab, for various advanced cancers. Researchers want to see how safe it is and if it has any effect on the cancer. It's a very early stage study.
United States · Belgium · Canada - authorisedTherapeutic exploratory (Phase II)
"Contribution of 68Ga-FAPI-46 PET-CT in the initial staging of gastric cancers eligible for curative treatment" "FAPGASTRO"
This study looks at a special type of scan called 68Ga-FAPI-46 PET-CT for people with stomach cancer. It wants to see if this scan helps doctors better understand the stage of the cancer before treatment, which could lead to better treatment plans.
France - recruitingPHASE1
A Study of NX-1607 in Adults With Advanced Malignancies
This study is looking into a new treatment called NX-1607 for various advanced cancers, including ovarian, stomach, and lung cancer. It aims to see how safe the treatment is and if it can help fight the cancer, sometimes combined with another drug called Paclitaxel.
United States · United Kingdom - recruitingPHASE2
AZD0901 in Participants With Advanced Solid Tumours Expressing Claudin18.2
This study is looking at a new medicine called AZD0901 for people with certain advanced cancers like stomach or pancreatic cancer. We want to see how safe it is, if it works, and how the body handles it, sometimes on its own and sometimes with other cancer drugs.
United States · Australia · Canada - ongoing, recruitingHuman Pharmacology (Phase I)- Other
A Phase 1b, Multicenter Study to Determine the Dose, Safety, Efficacy and Pharmacokinetics of TRK-950 when Used in Combinations with Selected Anti-Cancer Treatment Regimens in Patients with Selected Advanced Solid Tumors
This study is testing a new medicine, TRK-950, in adults with advanced cancers like bladder, bowel, stomach, and ovarian cancer. Researchers want to find the right dose, understand if it's safe, and see how well it works when given alongside other cancer treatments.
France - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A Phase 1 Study of SGN-ALPV in Advanced Solid Tumors
This early-stage study is testing a new treatment called SGN-ALPV for advanced solid cancers, including certain stomach, lung, and gynaecological cancers. It's looking closely at how safe the treatment is and what side effects it might cause when first given to people.
Spain · Sweden · Netherlands - ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Multicenter, Open-Label Study of DKN-01 in Combination with Tislelizumab ± Chemotherapy as First-Line or Second-Line Therapy in Adult Patients with Inoperable, Locally Advanced or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma (DisTinGuish)
This study is testing new combinations of medicines for advanced stomach or gastroesophageal junction cancer. It's looking at how safe they are and how well they help control the cancer, especially in people with a specific marker called DKK1-high.
Germany - ongoing, recruitingTherapeutic exploratory (Phase II)
68Ga-FAPI PET/CT: The Diagnostic Accuracy for Primary Staging and Re-staging after Chemotherapy in Patients with Gastric and Gastro-esophageal Junctional Cancer
This study is looking at new ways to scan people with stomach or food pipe cancer. It compares two types of special scans (FAPI PET/CT and FDG PET/CT) to see which one is better at finding cancer and checking how well treatments are working. The aim is to improve how doctors understand and treat these cancers.
Denmark - ongoing, recruitingHuman Pharmacology (Phase I)- First administration to humans
A study to Evaluate AB308 in Combination with AB122 in Participants with Advanced Malignancies (ARC-12)
This early-stage study is testing a new combination of medicines, AB308 and AB122, for people with several types of advanced cancer, including blood cancers and solid tumours. It aims to see if the treatment is safe and how the body reacts to it.
Spain · Poland - active not recruitingPHASE1
Study of Cabozantinib Alone or in Combination With Atezolizumab to Subjects With Locally Advanced or Metastatic Solid Tumors
This study is testing two anti-cancer drugs, cabozantinib and atezolizumab, alone and together, for various advanced cancers. It aims to find a safe combination dose and see how well it works and any side effects.
United States · Australia · Belgium - active not recruitingPHASE1, PHASE2
Study of AZD5305 as Monotherapy and in Combination With Anti-cancer Agents in Patients With Advanced Solid Malignancies
This study is looking into a new drug, AZD5305, by itself or with other cancer treatments, for advanced solid cancers like ovarian, breast, and lung cancer. It aims to see if it's safe, tolerable, and effective.
United States · Australia · Canada - recruitingPHASE1
A Study of MGC026 in Participants With Advanced Solid Tumors
This study is testing a new medicine called MGC026 for people with advanced cancers that have come back or spread. Doctors want to see if it's safe, what side effects it causes, and if it can help slow down or shrink tumors.
United States · Australia · United Kingdom - not yet recruiting
MRinRT: Swansea University and SWWCC Collaboration Study.
This study looks at using MRI scans to make radiotherapy for cancers like brain, stomach, and gullet cancer more accurate. It aims to see if MRI can help doctors better plan and adjust treatment, potentially reducing side effects.
United Kingdom - recruitingPHASE2
A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors
This study is looking at a new treatment called HER3-DXd for people with certain advanced solid tumours that haven't responded to other treatments. It aims to see how well it works and if it's safe for different types of cancer, like melanoma, lung cancer, and breast cancer.
United States · Australia · Belgium - recruitingNA
Stereotactic Body Radiotherapy in Patients With Rare Oligometastatic Cancers (OligoRARE)
This study looks at adding special radiation to standard care for rare cancers that have spread a little. It wants to see if this addition helps people live longer compared to standard care alone.
Belgium · France · Germany - recruitingPHASE1, PHASE2
A Study of Bispecific Antibody MCLA-158 in Patients With Advanced Solid Tumors
This study is looking at a new drug called MCLA-158 for advanced cancers like bowel and head and neck cancer. It aims to find the safest dose and see how well it works alone or with other treatments. It's for patients whose cancer has spread or come back.
United States · Belgium · France - recruiting
REVOLUTION Surgery (REVOLUTION Surgery)
This study looks into why some cancer patients lose weight and muscle, a condition called cachexia. It aims to understand this problem better by gathering information from patients undergoing surgery for certain cancers and comparing it with people having surgery for non-cancer conditions.
United Kingdom - recruitingPHASE1, PHASE2
Study for AZD4360 in Participants With Advanced Solid Tumours
This study is testing a new drug, AZD4360, for people with advanced stomach, bile duct, or pancreatic cancers that have a specific marker called CLDN18.2. It aims to see how safe it is and if it helps shrink tumors.
United States · China · Germany - active not recruitingPHASE3
Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer.
This study looks at a new drug, bemarituzumab, in combination with standard chemotherapy and nivolumab for advanced stomach or food pipe cancer. It aims to see if this new combination is safe and works better than current treatments, helping people with specific types of cancer live longer.
United States · Argentina · Australia - not yet recruitingPHASE2
Neoadjuvant Systemic and Peritoneal Chemotherapy for Advanced Gastric Cancer
This study looks at a new way to treat advanced stomach cancer that has spread to the lining of the abdomen. It combines standard chemotherapy with a special treatment delivered directly into the abdomen, aiming to improve outcomes for a specific group of patients.
United Kingdom - active not recruitingPHASE1, PHASE2
A Phase I/IIa Trial of HMBD-001 in Advanced HER3 Positive Solid Tumours
This study is testing a new drug, HMBD-001, for advanced cancers where a protein called HER3 is active. We want to find the best dose, understand side effects, and see if it helps stop cancer growth, sometimes with another drug called enzalutamide.
United Kingdom - recruitingPHASE3
Study of TDXd, Chemotherapy, Pembrolizumab, and Trastuzumab in First-Line Metastatic HER2-Positive Gastric or Gastroesophageal Junction Cancer
This study looks at new drug combinations for stomach or food pipe cancer that has spread. It compares an experimental treatment with standard care, aiming to find better ways to treat patients whose cancer has specific features.
United States · Argentina · Australia - active not recruitingPHASE2, PHASE3
A Study of Evorpacept (ALX148) in Patients With Advanced HER2+ Gastric Cancer (ASPEN-06)
This study, called ASPEN-06, looked into an experimental drug called Evorpacept for people in the UK with advanced stomach cancer (gastric cancer) that has a specific genetic marker (HER2-positive). It aimed to see if adding Evorpacept to standard treatments improved outcomes. The study has now been stopped due to strategic reasons.
United States · Australia · Belgium - recruitingPHASE3
Sonesitatug Vedotin in Combination With Capecitabine With or Without Rilvegostomig in Participants With Advanced or Metastatic Gastric, Gastroesophageal Junction, or Esophageal Adenocarcinoma Expressing Claudin18.2
This study is testing new combinations of medicines (sonesitatug vedotin, rilvegostomig, and capecitabine) for advanced stomach, gastroesophageal junction, or oesophageal cancers. It aims to see how well they work and if they are safe for people whose cancer has a specific marker called Claudin18.2.
United States · Australia · Austria